
    
      The patient population will include the patients with a histologically documented diagnosis
      of WDNET, defined according to the last WHO Classification criteria for NET of
      gastro-entero-pancreatic, bronchial, thymic or other origin; and showing tumor progression
      under a standard dose treatment with LAR (30 mg every 28 days) for at least 6 months.
      Progressive disease will be defined as increased tumor size according to RECIST definitions.
    
  